A recent study showed that 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate antagonizes YB-1, inhibits YB-1 nuclear translocation and increases doxorubicin accumulation in breast cancer cells (Gunasekaran et al., 2018). The gene discussed is YBX1; the disease is breast carcinoma.